adjuv
current
use
market
human
vaccin
critic
need
exist
novel
immunopotenti
deliveri
vehicl
capabl
elicit
humor
cellular
mucos
immun
crucial
vaccin
compon
could
facilit
develop
novel
vaccin
viral
parasit
infect
hepat
hiv
malaria
cancer
etc
review
discuss
clinic
trial
result
variou
vaccin
adjuv
deliveri
vehicl
develop
approxim
nanoscal
nm
size
humor
immun
respons
observ
adjuv
deliveri
platform
viral
vector
iscom
isa
shown
cytotox
cell
respons
clinic
elicit
respons
viruslik
particl
nondegrad
nanoparticl
liposom
also
gener
cellular
immun
vaccin
compon
also
evalu
altern
rout
administr
clinic
success
report
intranas
deliveri
viral
vector
proteosom
oral
deliveri
vlp
vaccin
publish
elsevi
bv
creation
vaccin
one
medicin
import
accomplish
influenc
human
aptli
express
vaccinologist
stanley
plotkin
say
impact
vaccin
health
world
peopl
hard
exagger
except
safe
water
modal
even
antibiot
major
effect
mortal
reduct
popul
growth
diseas
measl
mump
rubella
diphtheria
tetanu
pertussi
haemophilu
influenza
type
b
hib
diseas
polio
yellow
fever
control
vaccin
smallpox
complet
erad
polio
verg
elimin
thank
aggress
vaccin
campaign
diseas
includ
influenza
hepat
b
viru
hbv
pneumococc
infect
least
partial
control
vaccin
still
much
need
done
elimin
mani
diseas
even
develop
world
throughout
histori
vaccin
develop
use
live
attenu
organ
kill
whole
organ
inactiv
toxin
refer
toxoid
live
vaccin
smallpox
polio
oral
measl
mump
rubella
varicella
adenoviru
other
advantag
produc
humor
cellular
immun
often
requir
one
boost
disadvantag
live
vaccin
includ
seriou
risk
revert
back
virul
form
intrins
instabl
make
difficult
deliv
kill
inactiv
whole
organ
vaccin
influenza
hepat
other
well
toxoid
vaccin
includ
diphtheria
tetanu
gener
weaker
immun
respons
typic
requir
multipl
dose
recent
effort
focus
util
technolog
recombin
dna
method
develop
dna
subunit
vaccin
well
conjug
vaccin
weak
antigen
link
stronger
immunogen
protein
membran
complex
vaccin
hib
respons
nearli
elimin
hib
mening
infant
young
children
exampl
conjug
vaccin
dna
vaccin
contain
gene
gene
encod
particular
antigen
far
licens
veterinari
use
howev
shown
promis
vaccin
wide
varieti
diseas
includ
tuberculosi
sar
subunit
vaccin
use
portion
pathogen
individu
protein
antigen
vaccin
attract
increas
safeti
sinc
revert
virul
form
lack
contamin
remain
origin
pathogen
organ
addit
abil
consist
produc
larg
well
defin
quantiti
antigen
recombin
method
highli
desir
develop
new
type
vaccin
exist
critic
need
addit
deliveri
vehicl
well
new
adjuv
mani
case
antigen
weakli
immunogen
therefor
adjuv
need
intensifi
immun
respons
adjuv
also
includ
vaccin
guid
type
immun
respons
gener
may
especi
import
develop
vaccin
cancer
hiv
mucos
immun
contrast
immunogen
antigen
may
benefit
specif
deliveri
vehicl
compon
may
facilit
target
andor
control
releas
antigen
antigen
present
cell
recent
studi
util
tolllik
receptor
ligand
shown
antigen
associ
ligand
produc
except
high
antibodi
titer
rapid
immun
respons
adjuv
deliveri
vehicl
also
shown
protect
antigen
degrad
although
gener
depend
natur
adjuv
exampl
chitosanalgin
nanoparticl
found
stabil
ovalbumin
studi
shown
model
protein
antigen
actual
destabil
tradit
aluminum
salt
adjuv
current
vaccin
adjuv
licens
use
human
although
aluminum
salt
approv
europ
aluminum
salt
use
licens
human
vaccin
unit
state
billion
dose
vaccin
contain
aluminum
salt
shown
elicit
earli
high
long
last
antibodi
titer
singl
immun
despit
frequent
global
use
mani
decad
mode
action
aluminum
salt
adjuv
well
understood
least
three
potenti
mechan
frequent
describ
literatur
one
idea
format
depot
site
inject
allow
antigen
releas
gradual
therebi
extend
time
possibl
antigen
interact
antigen
present
cell
lymphocyt
second
propos
mechan
attribut
particul
natur
aluminum
salt
particl
smaller
easili
phagocytos
macrophag
dendrit
cell
uptak
antigen
adsorb
particul
adjuv
increas
rel
antigen
solut
therebi
improv
effici
antigen
recognit
present
third
suggest
mechan
action
direct
stimul
immun
system
enhanc
cytokin
product
specif
aluminum
salt
adjuv
known
primarili
stimul
humor
respons
increas
product
cytokin
enhanc
cytokin
product
may
favor
treatment
extracellular
infect
cellular
immun
respons
may
prefer
immun
diseas
state
eg
hiv
malaria
cancer
etc
fourth
mechan
action
recent
propos
studi
reveal
destabil
protein
adsorb
aluminum
salt
adjuv
structur
perturb
occur
upon
adsorpt
may
fact
increas
antigen
suscept
proteolyt
process
immun
system
lead
enhanc
antigen
present
besid
bia
type
immun
respons
elicit
aluminum
salt
adjuv
disadvantag
use
includ
instabl
freez
dri
inconsist
produc
humor
immun
addit
despit
maintain
good
safeti
profil
seven
decad
still
safeti
concern
regard
use
aluminum
salt
although
evid
conflict
symptom
erythema
allerg
respons
hypersensit
contact
granulomat
inflamm
subcutan
nodul
well
macrophag
myofasc
report
patient
receiv
aluminum
saltcontain
vaccin
due
infrequ
occurr
side
effect
verdict
remain
aluminum
salt
exhibit
particularli
good
safeti
profil
aluminum
salt
offer
appropri
immun
enhanc
type
vaccin
clearli
adequ
critic
need
exist
altern
immunopotenti
antigen
deliveri
agent
current
trend
toward
go
small
mani
effort
develop
novel
adjuv
focus
system
microand
nanoscal
particul
system
order
micron
size
offer
sever
advantag
vaccin
deliveri
exampl
microparticl
approxim
size
mani
pathogen
immun
system
equip
attack
addit
larger
particl
gener
provid
longer
durat
antigen
releas
equival
smaller
one
dramat
influenc
immunogen
moreov
microparticl
shown
elicit
vigor
cellular
humor
immun
smaller
particl
order
nm
size
pursu
vaccin
deliveri
system
immunopotenti
focu
review
addit
characterist
share
nanosystem
discuss
herein
least
preliminarili
test
clinic
except
polymer
nanoparticl
viralvector
vaccin
consist
nonrepl
viru
contain
defin
genet
materi
pathogen
immun
desir
vaccin
also
commonli
refer
live
recombin
vaccin
sinc
immun
system
evolv
respond
virus
would
seem
ideal
way
deliv
antigen
advantag
virallyvector
vaccin
includ
eas
product
good
safeti
profil
least
case
abil
potenti
strong
immun
respons
potenti
nasal
epicutan
deliveri
mucos
immun
case
viralvector
vaccin
compar
dna
vaccin
viral
vector
shown
significantli
enhanc
immunogen
adenoviru
administ
oral
vaccin
decad
also
provid
frequent
vector
platform
mani
type
vaccin
includ
deliveri
system
alzheim
diseas
influenza
tetanu
hiv
base
vaccin
system
also
use
altern
rout
administr
ie
parenter
rout
typic
use
immun
recent
phase
clinic
trial
adenovirusvector
flu
vaccin
administ
intranas
epicutan
found
elicit
high
serum
antibodi
titer
good
safeti
profil
studi
first
kind
show
adenovirusvector
vaccin
safe
intranas
epicutan
administr
human
preclin
studi
adenovirusvector
tetanu
vaccin
report
similar
result
addit
adenoviru
varieti
vector
shown
success
preclin
clinic
studi
modifi
vaccinia
viru
ankara
mva
welltoler
produc
good
safeti
profil
human
infect
undergo
highli
activ
antiretrovir
therapi
haart
addit
canarypox
vector
use
express
cytomegaloviru
cmv
antigen
result
clinic
result
manifest
specif
cytotox
cell
ctl
respons
especi
import
develop
immun
intracellular
viral
pathogen
first
vaccin
produc
effect
cmv
preclin
studi
also
shown
promis
use
cmv
vector
immunocontracept
vaccin
yellow
fever
viru
vector
express
dengu
viru
envelop
gene
addit
viralvector
technolog
current
pursu
vaccin
deliveri
includ
poxvirus
measl
viru
vesicular
stomat
viru
hsv
alphaviru
among
other
immun
respons
gener
virallyvector
vaccin
found
increas
primeboost
regimen
employ
procedur
involv
prime
immun
system
one
vector
vaccin
often
dna
vector
boost
pathogen
genet
materi
anoth
type
vector
recombin
protein
approach
success
hiv
vaccin
monkey
work
well
human
hiv
immun
recent
clinic
studi
publish
last
year
demonstr
primeboost
regimen
hiv
vaccin
employ
dna
mva
result
multifunct
cell
capabl
rapid
prolifer
eight
eight
vaccin
recipi
malaria
vaccin
administ
use
dose
regimen
also
show
promis
clinic
preclin
trial
viralvector
vaccin
use
immun
tuberculosi
ebola
siv
use
primeboost
strategi
also
appear
promis
virtual
case
primeboost
regimen
result
strong
cell
andor
respons
lead
current
statu
especi
promis
technolog
viruslik
particl
vlp
virosom
also
use
natur
mechan
structur
principl
trigger
immun
system
protect
effect
like
viralvector
vaccin
macromolecular
complex
stimul
immun
respons
deliv
materi
mimic
certain
viral
properti
vlp
essenti
noninfect
virus
consist
selfassembl
viral
envelop
protein
without
accompani
genet
materi
case
virosom
envelop
one
viru
use
platform
addit
compon
viru
anoth
viru
pathogen
attach
insert
type
particl
maintain
morpholog
cellpenetr
abil
similar
infect
viral
particl
vlp
virosom
also
shown
stimul
cellular
humor
immun
number
virosomebas
vaccin
alreadi
reach
market
first
hepat
vaccin
regist
berna
biolog
ltd
bern
switzerland
sever
european
asian
south
american
countri
compani
also
licens
influenza
vaccin
v
switzerland
avail
countri
anoth
flu
vaccin
util
virosom
regist
netherland
switzerland
intranas
flu
virosom
vaccin
coadminist
nativ
e
coli
heatlabil
enterotoxin
lt
mucos
adjuv
market
switzerland
berna
remov
market
increas
occurr
bell
palsi
observ
peopl
recent
receiv
vaccin
addit
sever
recombin
hbv
vlp
vaccin
licens
first
licens
recombin
hbv
vaccin
recombivax
merck
engerixb
gsk
compos
viral
small
envelop
protein
upon
express
yeast
form
nm
vlp
effect
suffer
lack
immunogen
nonrespond
determin
due
absenc
pre
epitop
surfac
vlp
immunogen
vlp
vaccin
subsequ
describ
contain
hbv
surfac
antigen
potenti
third
gener
hbv
vaccin
biohepb
found
elicit
strong
antibodi
respons
seroconvers
seroprotect
rate
although
yet
reach
market
recent
approv
vlp
vaccin
immun
human
papillomaviru
hpv
subsequ
prevent
cervic
cancer
genit
wart
vaccin
compos
primarili
selfassembl
particl
major
capsid
protein
hpv
type
also
contain
aluminum
salt
adjuv
shown
reduc
infect
hpv
appar
almost
effect
type
sinc
two
four
antigen
hpv
vaccin
hpv
type
implic
cervic
cancer
vaccin
expect
drastic
reduc
occurr
life
threaten
diseas
women
subsequ
gener
signific
excit
sever
vlp
vaccin
made
clinic
norwalk
viru
vaccin
shown
humor
mucos
cellular
immun
respons
administ
oral
suggest
vlp
may
use
deliveri
vaccin
mucos
immun
anoth
studi
show
small
peptid
der
allergen
coval
attach
bacteriophag
vlp
welltoler
gener
high
antibodi
titer
human
addit
malaria
vaccin
compos
vlp
hbv
core
antigen
contain
protein
circumsporozoit
stage
plasmodium
parasit
shown
produc
signific
humor
cellular
immun
respons
formul
studi
reveal
singl
dose
vaccin
administ
montanid
isa
see
immunogen
result
produc
multipl
immun
alhydrogeladsorb
vaccin
similarli
recombin
hybrid
ty
vlp
use
hiv
immun
found
produc
cellular
humor
immun
respons
compon
includ
vlp
varieti
vlp
vaccin
evalu
preclin
studi
tabul
method
public
grgacic
et
al
tabl
provid
comprehens
summari
use
vlp
vaccin
statu
develop
among
list
preclin
studi
vlp
influenza
hepat
c
viru
hcv
ebola
viru
rotaviru
sar
coronaviru
vaccin
deliveri
vehicl
includ
licens
vaccin
formul
nanos
vaccin
adjuv
approv
human
use
thu
far
although
yet
licens
unit
state
oilinwat
emuls
compos
nm
droplet
form
squalen
vv
two
surfact
polysorb
vv
tween
sorbitan
trioleat
vv
span
emulsifi
citrat
buffer
strong
immunogen
enhanc
clearli
seen
preclin
data
publish
ott
et
al
report
guinea
pig
show
increas
antibodi
titer
immun
glycoprotein
herp
simplex
viru
hsv
type
presenc
compar
aluminum
hydroxid
goat
baboon
show
increas
respect
mechan
adjuvant
believ
direct
stimul
cytokin
product
similar
result
also
observ
clinic
vaccin
hiv
hsv
cmv
antibodi
titer
measur
seroneg
patient
often
greater
infect
seroposit
patient
addit
strong
helper
cell
respons
also
detect
seroneg
patient
result
vaccin
influenza
vaccin
licens
europ
well
experiment
vaccin
avian
influenza
viru
hbv
produc
similar
behavior
clinic
base
studi
safeti
toler
adjuvant
human
seem
well
establish
studi
evalu
vaccin
deliv
parenter
anoth
clinic
studi
evalu
immunogen
flu
vaccin
administ
intranas
vaccin
also
welltoler
result
indic
mucos
immun
respons
may
gener
upon
administr
rout
may
optim
elicit
humor
immun
respons
studi
howev
found
enhanc
potenc
vaccin
presenc
compar
unadjuv
vaccin
administ
anoth
vaccin
deliveri
vehicl
potent
adjuv
activ
studi
clinic
immunostimul
complex
iscom
nm
cagelik
particl
produc
combin
protein
antigen
cholesterol
phospholipid
saponin
adjuv
quil
deriv
bark
south
american
quillaia
saponaria
molina
tree
matrix
form
trap
protein
antigen
typic
hydrophob
membran
protein
apolar
interact
similar
vaccin
deliveri
vehicl
adjuv
also
develop
use
materi
minu
antigen
refer
antigen
ad
later
formul
vaccin
materi
seem
work
similarli
iscom
provid
gener
applic
remov
requir
hydrophob
antigen
clinic
studi
compar
classic
trival
flu
vaccin
iscom
adjuv
version
compos
three
viru
strain
reveal
stronger
immun
respons
iscom
vaccin
elicit
rapid
antibodi
respons
well
helper
ctl
respons
separ
studi
iscom
base
flu
vaccin
show
virusspecif
ctl
memori
achiev
patient
compar
receiv
standard
flu
vaccin
addit
vaccin
clinic
hiv
hsv
hpv
hcv
cancer
util
antigen
case
studi
shown
good
safeti
toler
profil
human
well
induct
humor
cellular
immun
respons
despit
success
actual
use
iscom
human
vaccin
deter
concern
regard
safeti
sinc
saponin
toxic
elev
level
nevertheless
certain
saponin
quil
shown
major
sign
toxic
human
dose
administ
administ
mice
flu
iscom
vaccin
found
elicit
strong
mucos
igg
iga
respons
well
system
ctl
respons
similar
result
also
observ
sheep
baboon
titer
much
lower
detect
mice
oral
administr
iscom
vaccin
also
shown
effect
rout
requir
use
high
frequent
dose
studi
sheep
also
indic
iscom
vaccin
may
abl
elicit
strong
mucos
immun
respons
administ
pelvic
presacr
space
could
use
immun
viral
infect
femal
genit
tract
monophosphoryl
lipid
immunostimul
receptor
agonist
compos
detoxifi
lipopolysaccharid
lp
salmonella
minnesota
lp
major
compon
cell
wall
gramneg
bacteria
strong
adjuv
highli
toxic
toxic
attribut
lipid
region
molecul
detoxif
result
maintain
adjuvant
versatil
vaccin
adjuv
may
either
includ
aqueou
formul
oilinwat
emuls
dynam
respons
phase
studi
hiv
vaccin
healthi
volunt
show
high
antibodi
titer
similar
infect
individu
individu
administ
vaccin
found
neutral
importantli
larg
percentag
patient
receiv
emuls
studi
report
advers
event
suggest
adjuv
may
welltoler
circumst
novel
adjuvantsdeliveri
vehicl
contain
also
develop
exampl
adjuv
develop
glaxosmithklin
consist
combin
either
aluminum
salt
purifi
compon
quil
describ
combin
clinic
varieti
vaccin
includ
one
hsv
hbv
streptococcu
pneumonia
malaria
hpv
furthermor
use
europeanlicens
hbv
vaccin
shown
enhanc
humor
respons
characterist
aluminum
salt
also
induc
strong
cellmedi
respons
characterist
anoth
combin
adjuv
known
contain
mycobacterium
phlei
cell
wall
skeleton
squalen
emuls
use
clinic
melanoma
ovarian
cancer
breast
cancer
includ
canadianlicens
latestag
melanoma
vaccin
formul
found
enhanc
cellular
humor
immun
respons
minim
toxic
depend
antigen
rel
formul
nanoparticl
gener
combin
stir
calcium
chlorid
sodium
phosphat
sodium
citrat
sinc
calcium
phosphat
natur
occur
bodi
issu
surround
safeti
materi
reduc
confus
calcium
phosphat
gel
adjuv
use
european
diphtheriapertussistetanu
dpt
vaccin
formul
calcium
phosphat
nanoparticl
less
b
nm
accord
et
al
diamet
biosant
pharmaceut
develop
cap
technolog
phase
studi
healthi
volunt
show
cap
safe
nontox
administ
subcutan
preclin
studi
indic
vaccin
contain
cap
result
immun
respons
similar
greater
adjuv
aluminum
salt
durat
respons
longer
addit
cap
shown
promis
mucos
adjuv
studi
mice
util
antigen
suggest
cap
administ
intravagin
elicit
protect
system
mucos
immun
vaccin
util
cap
preclin
studi
includ
anthrax
hbv
flu
avian
season
varieti
polym
exist
nanoparticl
drug
deliveri
synthes
howev
commonli
studi
polym
poli
llactidecoglycolid
plg
polylactid
pla
biodegrad
biocompat
polym
approv
use
human
eg
sutur
bone
implant
screw
well
implant
sustain
drug
deliveri
extens
studi
use
formul
vaccin
antigen
ie
protein
peptid
dna
etc
formul
antigen
either
entrap
adsorb
surfac
particl
furthermor
particl
tailor
degrad
rang
rate
therefor
act
depot
encapsul
antigen
gradual
releas
addit
polymer
particl
may
offer
protect
encapsul
antigen
deliv
oral
facilit
uptak
mcell
nasalassoci
lymphoid
tissu
nalt
administ
nasal
thu
serv
vehicl
mucos
immun
adsorb
antigen
howev
may
offer
improv
stabil
activ
encapsul
antigen
avoid
exposur
organ
solvent
use
formul
acid
ph
condit
caus
degrad
polym
preclin
studi
shown
plg
nanoparticl
induc
system
antibodi
titer
compar
aluminum
salt
addit
studi
use
tetanu
toxoid
tt
found
synergist
immun
respons
ie
fourfold
higher
mean
serum
antitt
igg
respons
could
achiev
inject
tt
bound
aluminum
salt
along
ttload
nanoparticl
anoth
studi
show
plg
nanoparticl
load
cancerassoci
antigen
mucin
peptid
effici
taken
dendrit
cell
materi
enter
clinic
vaccin
applic
therefor
discuss
greater
detail
contrast
biodegrad
nanoparticl
variou
nondegrad
nanoparticl
evalu
use
vaccin
adjuv
deliveri
system
among
materi
examin
gold
latex
silica
polystyren
sinc
materi
may
remain
tissu
extend
period
time
thought
antigen
may
present
immun
system
similar
time
period
therebi
enhanc
immunogen
gold
particl
frequent
describ
vaccin
deliveri
without
aid
electropor
shown
often
dramat
enhanc
potenc
dna
vaccin
improv
deliveri
cellular
interior
combin
electropor
intraderm
deliveri
dna
gold
particl
enhanc
acceler
immun
respons
observ
mice
howev
electropor
may
applic
human
clinic
set
due
cell
mortal
result
highvoltag
electr
puls
studi
human
use
particl
without
electropor
produc
rel
low
respons
rate
vaccin
dnagold
particl
granulocytemacrophag
colonystimul
factor
gmcsf
transfect
autolog
tumor
cell
altern
approach
deliv
dna
vaccin
employ
nondegrad
nanoparticl
particl
bombard
also
refer
particlemedi
epiderm
deliveri
pmed
gene
gun
approach
method
involv
ballist
fire
dnacoat
gold
nanoparticl
epidermi
deliveri
effici
techniqu
quit
low
small
amount
dna
requir
achiev
signific
immun
respons
clinic
trial
shown
approach
elicit
humor
cellular
immun
respons
make
one
consist
success
dna
vaccin
deliveri
approach
current
avail
success
base
ballist
method
observ
vaccin
hbv
influenza
malaria
latter
involv
primeboost
regimen
liposom
sometim
classifi
vlp
spheric
entiti
compos
phospholipid
bilay
shell
aqueou
core
review
liposom
consid
compos
nonvir
lipid
ie
lipid
obtain
passiv
host
cell
viral
bud
process
vaccin
deliveri
antigen
adjuv
may
either
encapsul
core
liposom
buri
within
lipid
bilay
adsorb
surfac
present
antigen
present
cell
deliveri
vesicl
consid
nontox
phospholipid
use
prepar
found
mammalian
cell
lipid
rel
nonimmunogen
thu
vaccin
purpos
particl
consid
use
deliv
antigen
adjuv
contrast
liposom
made
immunogen
modifi
surfac
particl
ad
ligand
antigen
anoth
type
lipid
nakanishi
et
al
demonstr
cation
liposom
much
potent
anion
neutral
liposom
gener
cellmedi
immun
respons
interest
preclin
studi
mice
conduct
guan
et
al
evalu
effect
liposom
formul
type
immun
respons
gener
therapeut
cancer
vaccin
studi
reveal
liposomeassoci
either
encapsul
surfaceexpos
peptid
produc
strong
specif
ctl
respons
howev
antibodi
respons
observ
surfaceassoci
formul
clinic
studi
confirm
also
known
lyophil
liposom
formul
lipopeptid
three
lipid
welltoler
elicit
cellular
immun
respons
patient
lung
cancer
develop
merck
biomira
treatment
nonsmal
cell
lung
cancer
nsclc
account
lung
cancer
phase
iib
trial
show
vaccin
increas
surviv
rate
patient
smaller
nonmetastat
nsclc
tumor
phase
iii
clinic
trial
current
underway
despit
number
liposomebas
product
market
us
current
liposomebas
vaccin
besid
nsclc
vaccin
describ
addit
liposom
vaccin
investig
human
trial
includ
vaccin
malaria
hiv
hepat
influenza
prostat
cancer
colorect
cancer
found
safe
highli
immunogen
common
form
proteosom
use
vaccin
applic
nanoparticl
compos
outer
membran
protein
omp
neisseria
meningitidi
omp
use
success
market
meningococc
vaccin
sinc
consid
nontox
welltoler
due
hydrophob
natur
omp
immunogen
deliveri
system
appropri
deliv
apolar
amphiphil
antigen
gener
use
noncoval
interact
proteosom
antigen
form
appropri
complex
deliveri
vehicl
qualifi
safe
welltoler
materi
variou
human
clinic
trial
case
trial
involv
administr
vaccin
sever
case
novel
adjuv
known
consist
proteosom
noncoval
complex
lp
use
exampl
vaccin
compos
shigella
flexneri
lp
conjug
proteosom
found
elicit
immun
respons
similar
observ
immun
live
pathogen
addit
monoval
trival
influenza
lp
vaccin
administ
produc
high
antibodi
titer
serum
well
nasal
secret
suggest
deliveri
proteosomebas
vaccin
may
abl
produc
system
mucos
immun
furthermor
preclin
studi
shown
vaccin
capabl
protect
mice
upon
challeng
infect
pathogen
anoth
similar
categori
vaccin
probabl
appropri
discuss
elsewher
due
nonparticul
charact
conjug
vaccin
vaccin
consist
rel
nonimmunogen
especi
infant
antigen
link
immunogen
carrier
protein
toxoid
world
best
sell
vaccin
prevnar
exampl
vaccin
prevnar
pneumococc
vaccin
manufactur
wyeth
consist
saccharid
capsular
antigen
seven
serotyp
pneumonia
conjug
mutant
diphtheria
toxoid
crm
addit
conjug
vaccin
h
influenza
type
b
hib
develop
use
hib
polysaccharid
conjug
either
diphtheria
toxoid
prpd
omp
n
meningitidi
prpomp
mutant
diphtheria
toxoid
crm
hboc
tetanu
toxoid
prpt
render
hib
antigen
immunogen
meningococc
vaccin
anoth
exampl
conjug
vaccin
quadrival
vaccin
manufactur
sanofi
pasteur
market
contain
four
meningococc
polysaccharid
conjug
diphtheria
toxoid
enhanc
immun
respons
sever
differ
type
includ
isa
isa
waterinoil
emuls
isa
waterinoilinwat
emuls
isa
use
veterinari
vaccin
formul
two
investig
use
human
emuls
isa
compos
metaboliz
squalenebas
oil
mannid
monool
emulsifi
isa
formul
slightli
differ
isa
permit
antigen
releas
rapidli
similar
incomplet
freund
adjuv
ifa
physic
charact
biodegrad
natur
elimin
mani
cytotox
properti
ifa
immun
enhanc
produc
emuls
believ
due
format
depot
site
inject
isa
shown
induc
high
antibodi
titer
ctl
respons
varieti
anim
speci
mani
case
respons
greater
achiev
use
type
adjuv
emuls
phase
andor
ii
clinic
trial
vaccin
malaria
hiv
variou
cancer
case
vaccin
found
safe
fairli
welltoler
phase
trial
trival
malaria
vaccin
contain
isa
induc
humor
cellular
immun
respons
trial
synthet
malaria
peptid
vaccin
wilm
tumor
protein
vaccin
variou
malign
melanoma
vaccin
contain
either
isa
show
strong
ctl
respons
human
cholesterol
conjug
varieti
carbohydr
includ
pullulan
dextran
mannos
render
molecul
amphiphil
molecul
shown
selfassembl
without
protein
nm
colloid
stabl
nanoparticl
whose
size
densiti
modifi
alter
degre
substitut
cholesterol
group
polysaccharid
pullulan
popular
polysaccharid
cholesterol
conjug
numer
report
publish
studi
conduct
vitro
singl
one
human
current
one
report
cholesterolbear
hydrophob
pullulan
nanoparticl
chp
evalu
clinic
complex
chp
shown
enhanc
humor
immun
respons
studi
cellular
immun
respons
evalu
due
seroposit
patient
possess
activ
cell
previous
vitro
studi
show
dendrit
cell
load
complex
induc
cell
preclin
studi
mice
show
immun
complex
oncoprotein
chp
induc
humor
respons
studi
vaccin
chp
seem
safe
welltoler
novel
vaccin
adjuv
particlebas
deliveri
vehicl
evalu
varieti
vaccin
includ
diseas
cancer
malaria
aid
hepat
etc
cellular
andor
mucos
immun
respons
desir
case
humor
respons
may
attain
use
aluminum
salt
adjuv
may
suffici
gener
protect
immun
clinic
studi
variou
nanoparticul
immunopotenti
antigen
deliveri
vehicl
shown
ctl
respons
viral
vector
iscom
isa
respons
elicit
addit
cellular
immun
respons
also
gener
human
use
vlp
virosom
nondegrad
nanoparticl
liposom
breadth
carrier
shown
desir
respons
show
promis
develop
new
improv
vaccin
wide
varieti
type
also
encourag
number
vaccin
deliveri
compon
adjuv
pursu
altern
rout
administr
mucos
immun
respons
mani
shown
viralvector
vaccin
well
proteosom
given
shown
capabl
produc
system
antibodi
human
moreov
vlp
vaccin
administ
oral
elicit
humor
cellular
mucos
immun
respons
clinic
preclin
studi
also
demonstr
mucos
immun
administr
iscom
cap
vaccin
well
intravagin
deliveri
cap
vaccin
particlebas
vaccin
deliveri
system
made
market
probabl
reason
clinic
trial
requir
vaccin
approv
often
long
difficult
unlik
preclin
studi
anim
challeng
infecti
pathogen
follow
immun
evalu
whether
vaccin
protect
human
trial
often
requir
wait
outbreak
protect
analyz
furthermor
sinc
mani
vaccin
often
administ
healthi
individu
frequent
infant
critic
proven
safe
welltoler
nonhuman
primat
enter
human
trial
develop
novel
vaccin
deliveri
system
adjuv
aid
nanotechnolog
field
also
result
concern
regard
toxic
small
particl
among
perceiv
potenti
problem
high
surfac
area
reactiv
abil
small
particl
cross
biolog
membran
slow
biodegrad
materi
argument
support
data
describ
effect
pollut
human
health
despit
issu
seem
reason
anticip
case
vaccin
infrequ
lowlevel
exposur
nanoparticl
individu
encount
immun
enough
caus
advers
health
problem
potenti
attribut
nanotox
effect
said
develop
novel
vaccin
adjuv
deliveri
platform
like
pharmaceut
product
must
prove
safeti
toler
approv
mani
challeng
must
met
new
class
vaccin
becom
avail
ideal
adjuv
deliveri
vehicl
abil
stimul
humor
cellular
mucos
immun
respons
concurr
discret
depend
upon
desir
treatment
strategi
durat
respons
long
vaccin
compon
easili
metabol
bodi
addit
challeng
includ
develop
altern
less
invas
approach
administr
vaccin
perhap
importantli
cost
produc
distribut
new
vaccin
remain
moder
benefit
avail
everyon
risk
includ
person
less
develop
part
world
challeng
met
prevent
therapi
mani
previous
untreat
diseas
becom
increasingli
possibl
recent
clinic
trial
adenovirusbas
hiv
vaccin
merck
prove
unsuccess
furthermor
evid
vaccin
subject
previous
expos
adenoviru
show
